In vitro activity and cross resistance studies with cefpodoxime.
On the basis of MIC determinations and appropriate MIC breakpoints, 370 pathogens showed complete cross resistance between cefpodoxime and cefuroxime axetil, cefotiam hexetil, cefixime and cefotaxime in 69.7%, 80.3%, 92.2% and 87% of the strains, respectively. Cefpodoxime was superior to cefuroxime axetil in 28.7%, to cefotiam hexetil in 17.6%, to cefixime in 7% of strains and to cefotaxime not at all. On the other hand, we found cefpodoxime to be inferior to the cephalosporins mentioned in 1.6%, 2.1%, 0.8% and 13%, respectively.
Grimm
H
H
Institute for Medical Microbiology and Clin. Chemistry (Laboratory Dr. Gaertner), Weingarten.
D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D015310:Cefotiam / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D006801:Humans; D008826:Microbial Sensitivity Tests; D000097623:Cefpodoxime
D000892:Anti-Infective Agents, Urinary; D020682:Cefixime; D002439:Cefotaxime; D015310:Cefotiam; D015296:Ceftizoxime; D002444:Cefuroxime; D002511:Cephalosporins; D000097623:Cefpodoxime